ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)

ARS Pharmaceuticals (SPRY) reported Finished Goods of $7.3 million for Q1 2025, up 39.49% sequentially from $5.2 million in Q4 2024.

ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 2 years of Finished Goods data on file, last reported at $7.3 million in Q1 2025.

  • For the quarter ending Q1 2025, Finished Goods changed N/A year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2025 stood at $7.3 million (changed N/A YoY), and the FY2024 full-year result was $5.2 million, changed N/A from the prior year.
  • Finished Goods climbed to $7.3 million in Q1 2025, from $5.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $7.3 million in Q1 2025 to a low of $5.2 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 ARS Pharmaceuticals 595.78 Mn 394.81 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2025 7.27 Mn
Dec 31, 2024 5.21 Mn